This article is more than 5 years old. Information may no longer be current.

Nevro receives FDA approval for next-generation spinal cord stimulation system

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Nevro Corp. announced it has received FDA approval for its next-generation Senza II Spinal Cord Stimulation System.

Delivering HF10 therapy, the Senza II system maintains the performance and durability of the current implantable pulse generator through a smaller and more refined footprint, according to a company press release.

“We are pleased to have received FDA approval for Senza II so quickly after our recent CE mark clearance. Senza II is a step forward that represents our company’s commitment to continuously advancing our product portfolio,” Rami Elghandour, president and CEO of Nevro, said in the release. “The smaller, refined footprint delivers the unparalleled performance of our current Senza system and is backed by the same best-in-class clinical evidence that you’ve come to expect from Nevro and HF10. The initial product feedback from our European customers has been excellent, and we look forward to launching Senza II in the United States.”

Reference:

www.prnewswire.com/news-releases/nevro-receives-fda-approval-for-senza-ii-spinal-cord-stimulation-system-delivering-hf10-therapy-300578766.html